NIH Center Sets New Goals for Global Health Research and Training
Global health research and training efforts should focus on combatting the growing epidemic of noncommunicable diseases, better incorporating information technology into research and training, and more effectively converting scientific discoveries into practice in low-resource settings, according to the Fogarty International Center’s new strategic plan, released today. Fogarty is the component of the National Institutes of Health solely focused on supporting global health research and training, and coordinating international research partnerships across the agency.
As research discoveries and aid efforts have reduced deaths from HIV/AIDS, populations in the developing world are increasingly suffering from noncommunicable diseases such as heart disease, cancer, diabetes, and mental illness.
“It is critical that we leverage the existing HIV research and care delivery platform to build the capacity needed to stem the tide of these new disease epidemics,” said Dr Roger I. Glass, who leads Fogarty and serves as the NIH associate director for global health research. “We must focus our attention on these pressing problems, which also plague us in the US, and discover new ways to prevent and treat them. Today, global health and local health are becoming one and the same and research anywhere can help people everywhere.”
Fogarty plans to reinvigorate its efforts to train more developing-country scientists in these new areas of global health, where the field is moving and where the most interesting discoveries are yet to be made, according to the plan.
“Our concept of investing in training outstanding young investigators, both US and foreign, and linking them early in their careers in research partnerships between their institutions has been a winning strategy that has had a major impact on the research enterprise for global engagement,” said Glass.
To read more, click here.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance